I-Paxlovid liyeza lophando elisetyenziselwa ukunyanga i-COVID-19 ephakathi ukuya kwephakathi kubantu abadala kunye nabantwana [abaneminyaka eli-12 ubudala nangaphezulu abanobunzima obungama-88 eekhilogram (40 kg)] ngeziphumo ezilungileyo zovavanyo lwentsholongwane oluthe ngqo lwe-SARS-CoV-2, kwaye basemngciphekweni omkhulu wokuqhubela phambili ukuya kwi-COVID-19 eqatha, kubandakanya ukulaliswa esibhedlele okanye ukufa. I-Paxlovid yophando kuba isaphononongwa. Kukho ulwazi olulinganiselweyo malunga nokhuseleko kunye nokusebenza kakuhle kokusebenzisa i-Paxlovid ukunyanga abantu abane-COVID-19 ephakathi ukuya kwephakathi.
I-FDA igunyazise ukusetyenziswa okungxamisekileyo kwe-Paxlovid kunyango lwe-COVID-19 ephakathi ukuya kwephakathi kubantu abadala kunye nabantwana [abaneminyaka eli-12 ubudala nangaphezulu abanobunzima obungama-88 eekhilogram (40 kg) ngovavanyo olunayo le ntsholongwane. ibangela i-COVID-19, kwaye ngubani osemngciphekweni omkhulu wokuqhubekela phambili kwi-COVID-19 eqatha, kubandakanya ukulaliswa esibhedlele okanye ukufa, phantsi kwe-EUA.

I-Paxlovid ayiloyeza elivunywe yi-FDA e-United States. Thetha nomboneleli wakho wezempilo malunga nokhetho lwakho okanye ukuba unemibuzo. Lukhetho lwakho ukuthatha iPaxlovid.

I-Paxlovid inamayeza amabini: i-nirmatrelvir kunye ne-ritonavir.

I-Nirmatrelvir [PF-07321332] yi-SARS-CoV-2 main protease inhibitor (Mpro) inhibitor (ekwaziwa njenge-SARS-CoV2 3CL protease inhibitor) esebenza ngokuthintela ukuphindaphindeka kwentsholongwane kumanqanaba okuqala esi sifo ukunqanda ukuqhubeka ukuya kwi-COVID- 19.

I-Ritonavir ilawulwa kunye ne-nirmatrelvir ukunceda ukucothisa imetabolism yayo ukuze ihlale isebenza emzimbeni ixesha elide kwindawo ephezulu ukunceda ukulwa intsholongwane.